On October 3, 2019, Novelion Therapeutics Inc. announced that it has filed its notice of meeting and definitive proxy statement with the applicable securities regulatory authorities in connection with the proposals to be voted on at the Company’s 2019 annual general meeting of shareholders, including the proposed liquidation and dissolution of the Company. The Company added that it expects to commence mailing the definitive proxy statement and information circular to shareholders on or about October 4, 2019. The Company stated that the liquidation proposal is among the proposals to be voted on at the Company’s annual meeting, to be held on November 5, 2019. The Company added that its Board has unanimously approved each of these proposals and recommended shareholders to vote for each of the proposals.